Guardant Health raises $90.7M in registered direct offering with Baillie Gifford

Guardant Health, Inc.

Raised ~$90.7M gross via 3,387,446 shares sold at $26.77 each to Baillie Gifford-managed accounts.
Net proceeds ~$90.6M; funds earmarked for general corporate purposes including working capital and capex.
Offering closed Dec 21, 2023; executed under effective shelf registration statement on Form S-3.
CEO Helmy Eltoukhy noted strong support from Baillie Gifford as Guardant expands precision oncology portfolio.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Guardant Health, Inc. entered into Common Stock Purchase Agreement with certain institutional investors valued at 3,387,446 shares at $26.77 per share, gross proceeds ~$90.7 million (effective 2023-12-20).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: 3,387,446 shares at $26.77 per share, gross proceeds ~$90.7 million
Effective: 2023-12-20

Exact text from the filing

On December 20, 2023, Guardant Health, Inc. (the “Company”) entered into a common stock purchase agreement (the “Purchase Agreement”) for the issuance and sale in a registered direct offering of 3,387,446 shares of the Company’s common stock, par value $0.00001 per share (the “Shares”), to certain institutional investors at an offering price of $26.77 per share, for gross proceeds of approximately $90.7 million.

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Guardant Health, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-301187

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.